John P Leonard Selected Research

Lenalidomide (CC 5013)

11/2023	Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma.
1/2021	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.
11/2020	Lenalidomide in follicular lymphoma.
6/2020	Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
10/2019	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
11/2018	Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.
1/2018	Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis.
4/2017	Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
11/2016	Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
1/2016	Lenalidomide plus Rituximab for Mantle-Cell Lymphoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John P Leonard Research Topics

Disease

56	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2023 - 02/2002
53	Lymphoma (Lymphomas) 04/2024 - 02/2002
51	Neoplasms (Cancer) 04/2024 - 02/2002
28	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 11/2023 - 09/2005
27	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2023 - 07/2005
22	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022 - 08/2004
13	Hodgkin Disease (Hodgkin's Disease) 10/2023 - 08/2002
10	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 09/2003
10	B-Cell Lymphoma (Lymphoma, B Cell) 11/2021 - 08/2005
7	Neutropenia 06/2020 - 05/2014
7	Multiple Myeloma 01/2018 - 10/2006
5	Disease Progression 01/2022 - 12/2008
4	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 02/2007 - 11/2002
3	Anemia 10/2019 - 07/2005
3	Diarrhea 10/2019 - 12/2015
3	Infections 10/2019 - 12/2006
3	Exanthema (Rash) 04/2017 - 11/2016
2	Second Primary Neoplasms (Neoplasms, Second) 10/2023 - 10/2019
2	Heart Failure 06/2023 - 01/2022
2	Fatigue 06/2020 - 11/2015
2	Colitis 12/2016 - 12/2015
2	Leukemia 10/2016 - 11/2015
2	Genetic Translocation (Chromosomal Translocation) 01/2016 - 03/2010
2	Fabry Disease (Fabry's Disease) 04/2015 - 03/2015
2	Thrombocytopenia (Thrombopenia) 05/2014 - 12/2010
2	Polycystic Kidney Diseases (Polycystic Kidney Disease) 08/2012 - 07/2010
2	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 11/2010 - 07/2009
2	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 10/2009 - 04/2004
2	Hematologic Neoplasms (Hematological Malignancy) 02/2008 - 08/2006
2	Cytopenia 02/2008 - 07/2005
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 08/2007 - 06/2005
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2007 - 06/2005
2	Burkitt Lymphoma (Burkitt's Lymphoma) 10/2006 - 09/2003

Drug/Important Bio-Agent (IBA)

48	Rituximab (Mabthera)FDA Link 12/2023 - 02/2002
23	Monoclonal AntibodiesIBA 01/2021 - 02/2002
17	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2023 - 05/2008
16	Prednisone (Sone)FDA LinkGeneric 12/2023 - 05/2008
15	Lenalidomide (CC 5013)FDA Link 11/2023 - 09/2007
14	Vincristine (Oncovin)FDA LinkGeneric 12/2023 - 07/2008
13	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 07/2008
11	Bortezomib (Velcade)FDA Link 01/2020 - 09/2006
10	epratuzumabIBA 11/2013 - 02/2002
8	Biomarkers (Surrogate Marker)IBA 06/2023 - 10/2015
8	Bendamustine Hydrochloride FDA Link 01/2021 - 01/2010
7	Etoposide (VP 16)FDA LinkGeneric 11/2021 - 05/2008
7	Proteins (Proteins, Gene)FDA Link 01/2019 - 09/2003
7	IodineIBA 01/2018 - 12/2004
6	idelalisibIBA 06/2018 - 06/2013
5	palbociclibIBA 12/2019 - 05/2012
5	ibrutinibIBA 01/2019 - 09/2014
5	tositumomab I-131 (Bexxar)FDA Link 04/2016 - 10/2005
4	Cyclin D1IBA 12/2019 - 03/2010
4	Dexamethasone (Maxidex)FDA LinkGeneric 08/2012 - 09/2007
4	AntigensIBA 04/2003 - 02/2002
3	ofatumumab FDA Link 10/2019 - 01/2017
3	ceramide glucosyltransferaseIBA 01/2019 - 04/2015
3	Transaminases (Aminotransferases)IBA 12/2016 - 12/2010
3	GlycolipidsIBA 01/2016 - 03/2015
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2014 - 10/2006
3	ORALIT (ORS)IBA 04/2012 - 08/2004
3	Procarbazine (Matulane)FDA Link 04/2012 - 05/2008
3	Immunoconjugates (Immunoconjugate)IBA 01/2012 - 02/2002
3	Iodine-131IBA 06/2010 - 04/2003
3	AntibodiesIBA 03/2006 - 04/2003
2	AnthracyclinesIBA 06/2023 - 06/2010
2	cc-486IBA 01/2023 - 01/2022
2	GlycosphingolipidsIBA 01/2022 - 04/2015
2	navitoclaxIBA 01/2021 - 12/2010
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 09/2013
2	Proteasome InhibitorsIBA 12/2019 - 02/2011
2	ChemokinesIBA 01/2019 - 09/2002
2	Interleukin-10 (Interleukin 10)IBA 01/2019 - 09/2003
2	EnzymesIBA 01/2019 - 04/2015
2	CytokinesIBA 01/2019 - 06/2009
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 10/2016 - 02/2004
2	Protein Isoforms (Isoforms)IBA 12/2015 - 11/2015
2	GalactosidasesIBA 04/2015 - 03/2015
2	milatuzumabIBA 01/2015 - 01/2009
2	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 04/2014 - 10/2006
2	Indicators and Reagents (Reagents)IBA 03/2011 - 12/2006
2	Inosine Triphosphate (ITP)IBA 10/2009 - 04/2004
2	Clarithromycin (Biaxin)FDA LinkGeneric 07/2008 - 02/2008
2	Immunoglobulin G (IgG)IBA 06/2007 - 09/2003
2	fludarabineIBA 08/2006 - 08/2005
2	apolizumabIBA 02/2002 - 02/2002
2	Humanized Monoclonal AntibodiesIBA 02/2002 - 02/2002

Therapy/Procedure

69	Therapeutics 04/2024 - 02/2002
27	Drug Therapy (Chemotherapy) 12/2023 - 08/2002
9	Immunotherapy 01/2019 - 02/2002
8	Radioimmunotherapy 12/2023 - 04/2003
5	Stem Cell Transplantation 04/2024 - 08/2006
5	Radiotherapy 04/2024 - 12/2006
4	Aftercare (After-Treatment) 10/2019 - 07/2005
4	Combination Drug Therapy (Combination Chemotherapy) 10/2016 - 05/2008
2	Cell Transplantation 12/2021 - 01/2021
2	Transplantation 01/2021 - 08/2006
2	Homologous Transplantation 01/2021 - 08/2006
2	Biological Therapy 01/2021 - 11/2015
2	Salvage Therapy 01/2021 - 04/2010
2	Splenectomy 02/2012 - 04/2008